Compare · JNJ vs NATR
JNJ vs NATR
Side-by-side comparison of Johnson & Johnson (JNJ) and Nature's Sunshine Products Inc. (NATR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and NATR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $630.04B, about 2832.8x NATR ($222.4M).
- Over the past year, JNJ is up 30.4% and NATR is down 12.7% - JNJ leads by 43.2 points.
- JNJ has hit the wire 16 times in the past 4 weeks while NATR has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 5 for NATR).
- Company
- Johnson & Johnson
- Nature's Sunshine Products Inc.
- Price
- $248.97-5.73%
- $12.83+0.94%
- Market cap
- $630.04B
- $222.4M
- 1M return
- -6.54%
- -4.82%
- 1Y return
- +30.43%
- -12.72%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 16
- 0
- Recent ratings
- 25
- 5
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Nature's Sunshine Products Inc.
Nature's Sunshine Products, Inc., a natural health and wellness company, primarily manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. The company offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. It also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. The company offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is based in Lehi, Utah.
Latest JNJ
- SEC Form 8-K filed by Johnson & Johnson
- Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026
- Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
- TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
- New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
- After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings Reports
- New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
- New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause
Latest NATR
- EVP, Chief Financial Officer Perkins Ruth Ann was granted 75,433 shares (SEC Form 4)
- SEC Form 3 filed by new insider Perkins Ruth Ann
- SVP, Chief Accounting Officer Lanoy Jonathan David was granted 7,210 shares, increasing direct ownership by 15% to 55,602 units (SEC Form 4)
- Large owner Prescott Group Capital Management, L.L.C. bought $293,800 worth of shares (20,000 units at $14.69) (SEC Form 4)
- Large owner Prescott Group Capital Management, L.L.C. bought $2,318,912 worth of shares (141,389 units at $16.40) (SEC Form 4)
- SEC Form 10-Q filed by Nature's Sunshine Products Inc.
- Nature's Sunshine Products Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
- Nature's Sunshine Reports Second Quarter 2026 Results
- Nature's Sunshine Appoints Ruth Perkins as Executive Vice President and Chief Financial Officer
- Nature’s Sunshine Appoints Janine Weber as Executive Vice President and President, North America